- Home
- GNLX vs ASRT Comparison
GNLX vs ASRT Comparison
Compare GNLX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- ASRT
- Stock Information
- Founded
- GNLX 2001
- ASRT 1995
- Country
- GNLX United States
- ASRT United States
- Employees
- GNLX N/A
- ASRT N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- ASRT Health Care
- Exchange
- GNLX Nasdaq
- ASRT Nasdaq
- Market Cap
- GNLX 184.4M
- ASRT 78.3M
- IPO Year
- GNLX 2023
- ASRT 1997
- Fundamental
- Price
- GNLX $3.64
- ASRT $0.73
- Analyst Decision
- GNLX Strong Buy
- ASRT Strong Buy
- Analyst Count
- GNLX 4
- ASRT 3
- Target Price
- GNLX $18.25
- ASRT $3.25
- AVG Volume (30 Days)
- GNLX 201.9K
- ASRT 299.2K
- Earning Date
- GNLX 03-31-2025
- ASRT 03-12-2025
- Dividend Yield
- GNLX N/A
- ASRT N/A
- EPS Growth
- GNLX N/A
- ASRT N/A
- EPS
- GNLX N/A
- ASRT N/A
- Revenue
- GNLX $8,000.00
- ASRT $125,763,000.00
- Revenue This Year
- GNLX N/A
- ASRT N/A
- Revenue Next Year
- GNLX N/A
- ASRT $1.84
- P/E Ratio
- GNLX N/A
- ASRT N/A
- Revenue Growth
- GNLX N/A
- ASRT N/A
- 52 Week Low
- GNLX $1.60
- ASRT $0.73
- 52 Week High
- GNLX $7.04
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- GNLX 45.34
- ASRT 33.19
- Support Level
- GNLX $3.51
- ASRT $0.74
- Resistance Level
- GNLX $4.37
- ASRT $0.83
- Average True Range (ATR)
- GNLX 0.45
- ASRT 0.04
- MACD
- GNLX -0.13
- ASRT -0.00
- Stochastic Oscillator
- GNLX 22.95
- ASRT 17.29
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.